期刊
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA
卷 38, 期 7, 页码 636-645出版社
ELSEVIER INC
DOI: 10.1016/j.jogc.2016.04.005
关键词
Induced abortion; medical abortion; mifepristone; misoprostol; methotrexate
Objective: Abortion is one of the most common medical procedures a woman experiences in her lifetime. Even though overall rates of abortion are decreasing slightly, medical abortion rates are expected to increase in Canada following approval by Health Canada of a combination of mifepristone and misoprostol for use in medical abortion. Methods: We conducted a literature review as part of the development of the 2016 Society of Obstetricians and Gynaecologists of Canada's Clinical Practice Guidelines on medical abortion. We searched the PubMed, MEDLINE, and Cochrane databases for articles published between 1986 and 2015 using the MeSH terms induced abortion, medical abortion, mifepristone, misoprostol, methotrexate, and prostaglandin. Additionally, we reviewed existing international medical abortion guidelines and searched reference lists. Results: The most commonly studied medical abortion regimens are combinations of mifepristone and misoprostol, methotrexate and misoprostol, mifepristone and prostaglandin, and misoprostol only. Each of these regimens is a potential therapeutic choice; the advantages and disadvantages of each regimen are discussed. Conclusion: Drugs used for medical abortion are safe; however, clinicians who provide medical abortion and those who provide care to women who have undergone medical abortion should have an understanding of the pharmacokinetics and clinical effects of the medications used to improve outcomes and mitigate risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据